- Home
- BALL vs NBIX Comparison
BALL vs NBIX Comparison
Compare BALL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BALL | NBIX |
|---|---|---|
| Founded | 1880 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 13.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BALL | NBIX |
|---|---|---|
| Price | $56.34 | $137.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 21 |
| Target Price | $64.50 | ★ $177.05 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | 2.40 | ★ 4.19 |
| Revenue | ★ $12,694,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $11.84 | $23.59 |
| Revenue Next Year | $4.47 | $18.65 |
| P/E Ratio | ★ $22.28 | $32.30 |
| Revenue Growth | 7.41 | ★ 19.61 |
| 52 Week Low | $43.51 | $84.23 |
| 52 Week High | $60.29 | $160.18 |
Technical Indicators
Market Signals| Indicator | BALL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 69.42 | 45.35 |
| Support Level | $54.94 | $129.17 |
| Resistance Level | $56.35 | $135.98 |
| Average True Range (ATR) | 1.19 | 3.56 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 85.53 | 59.76 |
Price Performance
Historical ComparisonAbout BALL Ball Corporation
Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments—beverage packaging, North and Central America (48% of 2024 revenue), beverage packaging, EMEA (29%), beverage packaging, South America (17%)—and it generated $12 billion in revenue in 2024.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.